Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial

To assess the efficacy and safety of 18 months of subcutaneous abaloparatide (ABL-SC) or placebo (PBO) followed by 6 months of alendronate (ALN) (preplanned interim analysis). ACTIVExtend, an extension of ACTIVE, enrolled patients who completed 18 months of ABL-SC or PBO in ACTIVE to receive up to 2...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Mayo Clinic proceedings 2017-02, Vol.92 (2), p.200
Hauptverfasser:	Cosman, Felicia, Miller, Paul D, Williams, Gregory C, Hattersley, Gary, Hu, Ming-Yi, Valter, Ivo, Fitzpatrick, Lorraine A, Riis, Bente Juel, Christiansen, Claus, Bilezikian, John P, Black, Dennis
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Alendronate Alendronate - administration & dosage Alendronate - adverse effects Alendronate - therapeutic use Bone Density - drug effects Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - therapeutic use Dosage and administration Drug therapy Female Health aspects Humans Injections, Subcutaneous Kaplan-Meier Estimate Middle Aged Osteoporosis Osteoporosis, Postmenopausal - complications Osteoporosis, Postmenopausal - drug therapy Osteoporotic Fractures - etiology Osteoporotic Fractures - prevention & control Parathyroid Hormone-Related Protein - administration & dosage Parathyroid Hormone-Related Protein - adverse effects Parathyroid Hormone-Related Protein - therapeutic use Parathyroid hormones Patient outcomes Postmenopausal women Proportional Hazards Models Spinal Fractures - etiology Spinal Fractures - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!